The Alzheimer’s Disease Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Alzheimer’s Disease Treatment Market:
https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report
According to The Business Research Company’s Alzheimer’s Disease Treatment Global Market Report 2024, The alzheimer’s disease treatment market size has grown strongly in recent years. It will grow from $5.93 billion in 2023 to $6.41 billion in 2024 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to advancements in research and understanding, drug approvals and market entry, government initiatives and funding, public awareness and education.
The alzheimer’s disease treatment market size is expected to see strong growth in the next few years. It will grow to $8.35 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to precision medicine approaches, rising healthcare expenditure, global burden of disease, genetic and biomarker research, emerging markets. Major trends in the forecast period include biotechnological breakthroughs, technological innovations, digital health technologies, precision medicine approaches, neuroinflammation modulation, collaborations and partnerships.
The increasing cases of Alzheimer's are a major factor contributing to the growth of the alzheimer’s disease treatment market. Alzheimer's is the most common type of dementia. The USA Alzheimer's Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer’s patients by 2025 due to the increase in the geriatric population. At the global level, the estimated new cases of Alzheimer’s are expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050. Therefore, the increasing prevalence of alzheimer’s disease is expected to drive the demand of the growth of global alzheimer’s disease treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=3409&type=smp
The alzheimer’s disease treatment market covered in this report is segmented –
1) By Drug Class: Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins
2) By Drug Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists
3) By Therapeutics: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Therapeutics
Increasing R&D investments and collaborations because of emerging treatment technologies is the alzheimer's disease (AD) treatment market key trends. The Alzheimer's Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer's studies. Technologies such as β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field with their peptidomimetic series. Manufacturing firms such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, and vTv Therapeutics are focusing more on R&D investments with their research molecules in clinical trials to achieve a breakthrough in the treatment of alzheimer's disease.
The alzheimer’s disease treatment market report table of contents includes:
1. Executive Summary
2. Market Characteristics
3. Market Trends And Strategies
4. Impact Of COVID-19
5. Market Size And Growth
6. Segmentation
7. Regional And Country Analysis
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Research Nester released a report titled “Dementia and Alzheimer’s Disease Treatment Market: Global Demand Analysis & Opportunity Outlook 2028″which delivers a detailed overview of global dementia and Alzheimer’s disease treatment market in terms of market segmentation by drug class, by distribution channel, and by region.Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis, and Porter’s five force model.As per the World Health Organization, around 50 million people have dementia globally.
The most common form of dementia is Alzheimer’s disease, which constitutes about 60-70% of the total cases.Get Exclusive Sample Report Data Of This Report @ https://www.researchnester.com/sample-request-2384Dementia and Alzheimer’s disease treatment market is anticipated to record a notable CAGR over the forecast period, i.e., 2020-2028.
Based on this, the segment for cholinesterase inhibitors is anticipated to observe significantly high growth which can be attributed to the increased use of Alzheimer’s medications such as donepezil, galantamine, and rivastigmine.On the basis of regional analysis, dementia and Alzheimer’s disease treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
However, the side effects linked with the use of these drugs such as nausea, insomnia, diarrhea, fatigue, and anorexia are estimated to restrict the growth of the market.This report also provides the existing competitive scenario of some of the key players of global dementia and Alzheimer’s disease treatment market which includes company profiling of Novartis AG (SWX: NOVN), Pfizer, Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Allergan plc (NYSE: AGN), Eli Lilly and Company (NYSE: LLY), F. Hoffmann-La Roche Ltd. (SWX: RO), AstraZeneca (LON: AZN), Biogen (NASDAQ: BIIB), Eisai Co., Ltd. (TYO: 4523) and INmuneBIO (NASDAQ: MB).
On the whole, the report depicts a detailed overview of the global dementia and Alzheimer’s disease treatment market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities, and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future.Get Exclusive Sample Report Data Of This Report @ https://www.researchnester.com/sample-request-2384Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates, and executives for their future investment while avoiding forthcoming uncertainties.
With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors.
The Alzheimer’s Disease Drug market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the alzheimer’s disease drug market include Allergan, Eisai, Novartis, Daiichi Sankyo,Pfizer, Johnson and Johnson, Lundbeck.S.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Alzheimer’s Disease Drug Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/alzheimers-disease-drug-market/download-sampleMarket DynamicsThe increase in the prevalence of Alzheimer's disease and the aging population is the primary factor driving the alzheimer's disease drug market.
According to the WHO, there are around 50 million Alzheimer's disease cases globally.
The growing demand for personalized drugs and affordable diagnostics tests contributes to the growth of the alzheimer's disease drug market.
